Results of Phase I trial shed positive light on UNI-494 for acute kidney injury [Yahoo! Finance]
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: Yahoo! Finance
Unicycive Therapeutics recently announced positive results from its Phase I trial of UNI-494, [a patented pro-drug of nicorandil which is currently in development for the treatment of acute kidney injury (AKI)]. Its use was shown to be safe and well-tolerated in both single ascending and multiple ascending doses. The trial results also showed that its absorption was fast and rapidly metabolised, and that plasma concentration increases when dose increases. The ageing global population will lead to an increase in the prevalence of AKI, leading to an expansion of the market as well as a growing need for more therapeutic options. Key opinion leaders interviewed by GlobalData have emphasised that a drug that specifically shows enhanced efficacy in kidney disease patients will most likely receive breakthrough or fast track designations and gain market share. UNI-494 exhibits therapeutic intervention activating the SUR2 subunit of the mitochondrial ATP-sensitive potassium channel (KATP
Show less
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical TherapeuticsGlobeNewswire
- Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.MarketBeat
- Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
UNCY
Sec Filings
- 12/20/24 - Form SCHEDULE
- 12/20/24 - Form SCHEDULE
- 11/21/24 - Form EFFECT
- UNCY's page on the SEC website